France's Biosimilar Substitution May Lead to Erosion of Amgen
February 24, 2014 at 15:47 PM EST
The worst headwind for any pharmaceutic company is patent expiration. After the patent cliff comes an onslaught competition from generics and biosimilars that eats into sales. France just became the first European nation that allow pharmacists to substitute prescribed brand biological medicines for biosimilar medicine. The substitution can be made